La cadena de opciones muestra datos clave de las opciones de acciones de Indie Semiconductor a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Indie Semiconductor..

Indie Semiconductor (NASDAQ:INDI) Bolsa, Cadena de Opciones

Indie Semiconductor

Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

INDI

OUST

SMCI

Explora las acciones más sobrevendidas en tecnología, con un RSI bajo 30. Descubre oportunidades de inversión en empresas infravaloradas.

3 acciones tecnológicas en las que te arrepentirás de no haber invertido este mes

indie Semiconductor, Inc. - Class A Common Stock

Indie Semiconductor Inc

Indie Semiconductor Inc Warrants (10/06/2026)

INDIA CAPITAL GROWTH FD by India Capital Growth Fund Ltd.

INDIE RANCH MEDIA INC by Indie Ranch Media, Inc.

INDITEX ORD

INDIA CEMENT S/GDR 144A by India Cement Ltd.

India Cements Ltd

India Fund Inc

Indiana Resources Ltd

Indico Resources Ltd

INDIGENOUS BLOOM HEMP CRP by INDIGENOUS BLOOM HEMP CORP

Indigenous Bloom Hemp Corp

Indigo Books & Music Inc

INDIGO EXPL INC by Indigo Exploration, Inc.

Indigo Exploration Inc

Indiva Ltd

Indivior PLC

Indivior PLC ADR

Indivior PLC Ordinary Share

INDIEPUB ENTMT INC by indiePub Entertainment, Inc.

indiePub Entertainment Inc

Financial Outlook
Genius Sports expects to generate Group Revenue of approximately $511 million and Group Adjusted EBITDA of approximately $86 million in 2024. This implies year-over-year Group Revenue and Adj. EBITDA growth of 24% and 61%, respectively. Genius Sports also expects to generate positive cash flow in the full year of 2024.
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>$ in millions</td>
<td>&nbsp;</td>
<td colspan="2">Q1 2024A</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">Q2 2024A</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">Q3 2024A</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">Q4 2024E</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">FY 2024E</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Group Revenue</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>120</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>95</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>120</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>176</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>511</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Group Adjusted EBITDA</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>7</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>21</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>26</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>32</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>86</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Guidance

GENI

Genius Sports Sees FY24 Revenue ~$511M Vs $509.95M Est.; Adj. EBITDA Of ~$86M

In the wake of Donald Trump's election victory, Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares have gained 12% to $72.67 in November, buoyed by optimism around pro-business policies anticipated under a Republican-led administration. 
Trump's promise to extend and expand the Tax Cuts and Jobs Act, including further corporate tax reductions, has renewed investor confidence in banking stocks like Wells Fargo, which stands to benefit from a <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">friendlier tax environment</a> and reduced regulatory constraints.
What To Know: Wells Fargo, one of the United States&#8217; major banks, could experience improved profit margins if corporate tax rates are lowered further. Historically, the bank has also benefited from favorable regulatory changes under Republican administrations.
With the potential rollback of stringent environmental regulations, Wells Fargo's energy financing arm, which includes investments in fossil fuel projects, could see increased activity, further boosting revenue.
Additionally, the heightened inflation likely driven by Trump's proposed tariffs could prompt the Federal Reserve to maintain higher interest rates. For Wells Fargo, as for other banks, higher rates generally mean increased net interest margins, enhancing profitability on loans. 
Read Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Wells Fargo&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WFC has a 52-week high of $74.27 and a 52-week low of $40.53.

Wells Fargo Stock Is Up 12% This Month: What's Going On?

Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 600 percent. This is a 183.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $120.20 million which beat the analyst consensus estimate of $118.94 million by 1.06 percent. This is a 18.16 percent increase over sales of $101.73 million the same period last year.

Earnings

Earnings Beats

Genius Sports Q3 EPS $0.05 Beats $(0.01) Estimate, Sales $120.20M Beat $118.94M Estimate

Nano Labs Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 146.5%

Stryve Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAX#NASDAQ">SNAX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Stryve Foods will report an earnings per share (EPS) of $-1.01.
Stryve Foods bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.56 in the last quarter, leading to a 1.16% drop in the share price on the following day.

<a href="https://www.benzinga.com/quote/SNAX/earnings">To track all earnings releases for Stryve Foods visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNAX

Insights into Stryve Foods's Upcoming Earnings

FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate FlexShopper to report an earnings per share (EPS) of $-0.15.
Anticipation surrounds FlexShopper's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 0.0% drop in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2024/1731442539_0.png" alt="eps graph" />
<h3>FlexShopper Share Price Analysis</h3>
Shares of FlexShopper were trading at $1.21 as of November 11. Over the last 52-week period, shares are up 18.03%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on FlexShopper</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on FlexShopper.
FlexShopper has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $2.5, the consensus suggests a potential 106.61% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and FlexShopper, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary presents essential metrics for and FlexShopper, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FlexShopper</td>
<td>Buy</td>
<td>29.46%</td>
<td>$29.80M</td>
<td>-48.55%</td>
</tr>
</tbody>
</table>

Key Takeaway:
FlexShopper is positioned at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it is at the top for Return on Equity. Overall, FlexShopper's performance is mixed compared to its peers, with strengths in Return on Equity but weaknesses in Revenue Growth and Gross Profit.
<h3>Discovering FlexShopper: A Closer Look</h3>
FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.
<h3>Unraveling the Financial Story of FlexShopper</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: FlexShopper displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.46%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: FlexShopper's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -8.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): FlexShopper's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -48.55%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): FlexShopper's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.61%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 29.24, FlexShopper faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/FPAY/earnings">To track all earnings releases for FlexShopper visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FPAY

An Overview of FlexShopper's Earnings

Editor&#8217;s note: This story has been updated to more accurately report a quote from Chris Christie that states he is not in favor of cannabis descheduling.
"The U.S. government has got to get its act together and decide what it really thinks on this issue," says <a href="https://www.benzinga.com/topic/chris-christie">Chris Christie</a>, former New Jersey governor and longtime conservative voice, addressing the state of cannabis in America under a new Trump administration. 
In an exclusive conversation with <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis</a> facilitated by <a href="https://www.covers.com/politics/us-election-betting-odds">Covers.com</a>, Christie outlines his perspectives on the future of cannabis regulation and cryptocurrency adoption, framing both within a broader trend of deregulation he expects to see under Trump's leadership. As the country moves forward, Christie believes cannabis and crypto are poised to experience significant changes though each industry will need to navigate its own unique challenges.
<h2 class="wp-block-heading">Christie On Cannabis: &#8216;Trump Will Attempt To Deschedule&#8217;</h2>
Christie begins by tackling the complexities surrounding cannabis regulation, a topic he's been openly conservative about throughout his political career. Although he's traditionally opposed to federal legalization, Christie notes a potential shift under President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>. "What I suspect he would really like to do is get it downgraded by the DEA so that it&#8217;s not illegal," Christie says. Cannabis remains a Schedule I substance, making it federally illegal despite a growing wave of state-level legalization. For Christie, the legal status presents an obstacle for the industry, particularly regarding banking and financial services. "The trouble the cannabis industry has now is that a lot of people still won't do business with them, because the proceeds are tainted by the fact they are created through a drug that is illegal in the United States."
Christie suggests that descheduling cannabis—removing it from the DEA's list of controlled substances—could provide a workable solution. By changing its classification, he believes, the federal government could make way for legitimate business operations without directly endorsing legalization. "What I think Trump will attempt to do, which I don't favor, is change marijuana to a non-scheduled drug that wouldn&#8217;t be illegal, and then banks and other institutions would be more free to do business with cannabis store owners and entrepreneurs," he says. This stance marks a shift in Christie's approach, where he appears to reconcile his conservative views on cannabis with a pragmatic view of the industry's needs.
<h2 class="wp-block-heading">Christie On Crypto: Finding A &#8216;Sweet Spot&#8217;</h2>
Beyond cannabis, Christie also weighs in on another hot-button topic: cryptocurrency. Known for its volatility and potential for high returns, crypto has seen a significant uptick in adoption over recent years. With Trump heading to the White House, Christie predicts a favorable environment for crypto's continued expansion. "I think it will develop because he&#8217;ll not be in favor of doing a lot of regulating on it," he says, suggesting that Trump's general stance on deregulation could encourage further growth in the crypto sector.
However, Christie is quick to add a note of caution. "He&#8217;s got to be careful because when real people start to lose their money, and if that were to happen with crypto, they&#8217;re going to want the government to step in." For Christie, the challenge lies in striking a balance between fostering innovation and protecting the public. He stresses what he calls the "sweet spot" where regulation is minimal enough to allow growth, yet sufficient to shield investors from potential losses. "He&#8217;s got to try to find a sweet spot where he can regulate it enough so that grandma is not getting ripped off, but not so much that he puts a cap on its ability to grow and be a driver of America&#8217;s economy."
<h2 class="wp-block-heading">Are Christie&#8217;s Evolving Views A Reflection Of GOP&#8217;s Evolution?</h2>
Christie's pragmatic approach to cannabis and cryptocurrency reflects a broader trend within the GOP: a preference for state-led decision-making combined with cautious federal oversight. On cannabis, he continues to support a state-by-state approach, emphasizing that each state should have the freedom to regulate or prohibit cannabis as it sees fit. "The decision should be left to each individual state on cannabis regulation." This perspective aligns with Christie's conservative stance, although he acknowledges that a federal descheduling effort might make life easier for the industry.
With the potential <a href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics">appointment of figures like RFK Jr. to key health positions</a> under a Trump administration, the regulatory landscape for both cannabis and crypto could evolve rapidly over the next four years. As Christie sees it, the approach Trump takes will shape not only the cannabis and crypto markets but also public sentiment and investor confidence. His vision, rooted in deregulation with a careful dose of oversight, aims to balance the drive for innovation with a commitment to public safety—a delicate act in today's rapidly shifting political and economic landscape.
Photo via Shutterstock

Cannabis

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Exclusives

Interview

EXCLUSIVE: Chris Christie Says Trump Will Remove Federal Restrictions On Marijuana, Find 'Sweet Spot' For Crypto Regulation (UPDATED)

Nano Labs Shares Halted On Circuit Breaker To The Upside, Stock Now Up 123.7%

Associated Cap Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) short percent of float has fallen 58.82% since its last report. The company recently reported that it has 6 thousand shares sold short, which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Associated Cap Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731442304_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Associated Cap Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Associated Cap Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Associated Cap Gr's peer group average for short interest as a percentage of float is 2.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Associated Cap Gr's Recent Short Interest

Williams Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) short percent of float has fallen 15.62% since its last report. The company recently reported that it has 17.67 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Williams Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731442299_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Williams Companies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Williams Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Williams Companies's peer group average for short interest as a percentage of float is 4.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Williams Companies?

WR Berkley's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) short percent of float has fallen 23.47% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>WR Berkley Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731442294_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for WR Berkley has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing WR Berkley's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, WR Berkley's peer group average for short interest as a percentage of float is 1.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About WR Berkley?

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12138033).pn<img src="https://pbs.twimg.com/media/GcNLzzIWUAA9vxq?format=jpg&amp;name=900x900" alt="Image" />

Biotech

General

CHEK

Check-Cap Granted US Patent #12138033 For "SYSTEM AND METHOD FOR POLYP AND COLON CANCEROUS GROWTH DETECTION THROUGH CAPSULE DYNAMICS". Also 'Uses a Neural Network to Determine a Probability Score'.

WIIM

BILL

BILL Holdings shares are trading higher on continued strength after the company last week reported better-than-expected Q1 financial results and issued FY25 guidance above estimates. Goldman Sachs maintained a Neutral rating on the stock but raised its PT from $60 to $77.

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf</a>

EVAX

Watching Evaxion Biotech; Zacks Small-Cap Research Gives Stock $7.25 Price Valuation

In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $21.00, and a low estimate of $15.00. Observing a 3.8% increase, the current average has risen from the previous average price target of $16.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1731441719_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Amicus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dennis Ding</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amicus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amicus Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Delving into Amicus Therapeutics's Background</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Financial Milestones: Amicus Therapeutics's Journey</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Amicus Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 36.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amicus Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.32%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Amicus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.88%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Amicus Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 2.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

FOLD

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts

ONMD

OneMedNet shares are trading higher after it announced continued investment in Bitcoin which is currently seeing record highs.

Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is expanding its search for a successor to CEO Bob Iger, considering external candidates as the company&#8217;s board, led by incoming Chairman James Gorman, aims to stabilize the succession process.
The move signals a shift from an internal competition among Disney&#8217;s top executives to a broader search, including external contenders such as Andrew Wilson, CEO of Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/media/disney-explores-wider-field-of-candidates-to-succeed-iger-d1876792" rel="noreferrer noopener">reports</a>.
According to the report, Disney has partnered with executive search firm Heidrick &amp; Struggles to evaluate potential external candidates, and at least two more contenders have been identified beyond Wilson.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution" rel="noreferrer noopener">AppLovin&#8217;s High Valuation and Expansion Beyond Gaming Prompt Analyst Caution</a>
The decision comes as Gorman, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41432091/disneys-leadership-shift-james-gorman-named-as-chairman-ceo-search-underway" rel="noreferrer noopener">set to take over</a> as Chairman in January, pushes for a comprehensive review of candidates, signaling his intent to find the right leader to guide Disney beyond Iger&#8217;s tenure.
The company has announced it plans to finalize its choice for the CEO role by early 2026, delaying its previous timeline.
Wilson, who has previously discussed potential deals with Disney and even interviewed for a senior role at ESPN in 2018, remains a strong external contender.
Recent talks have also explored partnerships between Electronic Arts and Disney&#8217;s ESPN, although these discussions have yet to materialize into a deal, the report states.
The WSJ report says that internally, Disney had four key executives vying for the CEO role: Dana Walden, Alan Bergman, Josh D&#8217;Amaro, and Jimmy Pitaro. Each company manages significant areas of Disney&#8217;s business, from streaming to theme parks.
Last week, Disney launched the <a target="_blank" href="https://www.benzinga.com/news/24/11/41720954/disney-creates-new-tech-hub-for-ai-and-ar" rel="noreferrer noopener">Office of Technology Enablement</a> to drive AI and XR innovation across media and parks.
Jim Cramer <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41432091/disneys-leadership-shift-james-gorman-named-as-chairman-ceo-search-underway" rel="noreferrer noopener">showed interest in</a> buying more Disney stock if it dips below $90, stressing the potential value of the company&#8217;s theme parks amid current challenges. Disney laid off 300 corporate employees in September, following earlier cuts of 140 staff in its TV division and 175 at Pixar this year.
The recent U.S. presidential election victory of Donald Trump has also introduced new uncertainties for Disney. Trump&#8217;s criticism of Taiwan and potential changes in trade policies could impact Disney&#8217;s strategic decisions, particularly regarding its international investments and partnerships.
Walt Disney Co stock gained over 10% year-to-date. Investors can gain exposure to the stock through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>).
Price Actions: DIS stock is down 0.23% at $100.63 at&nbsp;the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>
Image via Shutterstock

Management

Media

Who Will Succeed Disney CEO Bog Iger?

Genius Group shares are trading higher after the company announced it adopted a Bitcoin treasury reserve strategy.

Alex Fazel, Chief Partnership Officer at Swissborg, sees Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) as the "best Trump proxy", highlighting its potential to <a href="https://www.benzinga.com/general/education/24/11/41882342/heres-how-much-100-in-dogecoin-today-could-be-worth-if-doge-hits-new-all-time-highs-2#:~:text=If%20Dogecoin%20can%20return%20to,more%20%E2%80%9CMuch%20Wow%E2%80%9D%20moments.">reach one dollar</a>.
What Happened: Fazel shared his portfolio in a <a href="https://x.com/tradetheflow_/status/1856290955244253659">post</a> on X, saying that meme coins make up a small and speculative portion of his holdings, while his primary investments are Bitcoin, Solana, Ethereum and a few DeFi and AI projects.
Fazel sees Goatseus Maximus (CRYPTO: GOAT) as an "OG meme" with staying power, recently gaining a Bybit listing and potentially a Binance spot listing soon.
His other meme holdings include Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>), Toshi (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TOSHI</a>) and Peanut The Squirrel (CRYPTO: PNUT) as a rising mascot meme. Toshi and Popcat are each &#8220;backed by strong communities,&#8221; according to the expert. 
He predicted, "After a long period of consolidation, the chart also looks ready to send."
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin About To Enter The &#8216;Euphoria&#8217; Stage</a>
The expert provides insight into the meme coin market, which has seen significant growth and volatility in recent years. His tweet serves as a reminder of the potential upside in the meme coin market, despite its inherent risks and volatility.
Price Action: Dogecoin is up 20% over the past 24 hours, trading at 38 cents.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41876486/dogecoin-explodes-for-86-weekly-gain-what-is-going-on">Dogecoin Explodes For 86% Weekly Gain: What Is Going On?</a></li>
</ul>

$DOGE

$POPCAT

$TOSHI

Dogecoin Is The 'Best Trump Proxy,' Industry Expert Claims

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Legal

Movers

AMED

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

Baron Technology Fund Q3 2024 Shareholder Letter

Baron Global Advantage Fund Q3 2024 Shareholder Letter

indie Semiconductor Q3 2024 Earnings Preview

Here are the major earnings after the close today

indie Semiconductor Non-GAAP EPS of -$0.09 in-line, revenue of $53.97M beats by $0.39M

indie Semiconductor ( ($INDI) ) has shared an update. Indie Semiconductor showcases robust growth by surpassing Q3 2024 revenue forecasts with a 3....

Indie Semiconductor Exceeds Q3 Revenue Expectations

indie Semiconductor, Inc. (INDI) Q3 2024 Earnings Call Transcript

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on BigCommerce Holdings (BIGC – Research Report), Dat...

Analysts' Opinions Are Mixed on These Technology Stocks: BigCommerce Holdings (BIGC), Datadog (DDOG) and indie Semiconductor (INDI)

JFrog slips as earnings season hops along while pair of semis rebound

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Eyes are on Nvidia (NVDA) during its f...

Comments

Indie Semiconductor

Indie Semiconductor (INDI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL